We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients.
- Authors
Mian, Shahid; Ugurel, Selma; Parkinson, Erika; Schlenzka, Iris; Dryden, Ian; Lancashire, Lee; Ball, Graham; Creaser, Colin; Rees, Robert; Schadendorf, Dirk
- Abstract
Currently known serum biomarkers do not predict clinical outcome in melanoma. S100-beta is widely established as a reliable prognostic indicator in patients with advanced metastatic disease but is of limited predictive value in tumor-free patients. This study was aimed to determine whether molecular profiling of the serum proteome could discriminate between early- and late-stage melanoma and predict disease progression.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Vol 23, Issue 22, p5088
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.03.164